Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response. Mizrahi AG, Hamad H, Gugenheim A, Nisman B, et al. Anticancer Res 2022;42:5257-5263.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mizrahi AG, Hamad H, Gugenheim A, Nisman B, et al. Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response. Anticancer Res 2022;42:5257-5263.
PMID: 36288893